Estimating the budget impact of innovative pharmacological treatments for patients with type 2 diabetes mellitus in Italy: the case of liraglutide (GLP-1).
<span> </span><p><strong>Background</strong></p><span> </span><p>Diabetes is among the most common chronic illnesses worldwide, with escalating rates around the world. Four years after the launch of liraglutide (a human GLP-1 analogue for type 2...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Milano University Press
2015-06-01
|
| Series: | Epidemiology, Biostatistics and Public Health |
| Online Access: | http://ebph.it/article/view/11082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|